Market Cap | 73.99K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -837k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | - |
Sales | 5.28M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -93.00% |
Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | - | 52W High Chg | -99.00% |
Recommedations | - | Quick Ratio | 0.15 | Shares Outstanding | - | 52W Low Chg | - |
Insider Own | - | ROA | - | Shares Float | - | Beta | 44.55 |
Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00010 |
Gross Margin | -11.37% | Profit Margin | -15.87% | Avg. Volume | 51 | Target Price | - |
Oper. Margin | -139.73% | Earnings Date | - | Volume | 1 | Change | 0.00% |
Health-Chem Corporation, through its subsidiary, Transderm Laboratories Corporation, engages in the research, development, manufacture, and marketing of transdermal drug delivery systems in the United States. It offers transdermal nitroglycerin patches used for transdermal relief of the vascular and cardiovascular symptoms related to angina pectoris (chest pain). The company also conducts research and development activities for third parties on a contract basis. Health-Chem Corporation markets its products directly to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, and group purchasing organizations, as well as indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit management companies. The company was founded in 1970 and is based in Emigsville, Pennsylvania.